Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 27, 2024Movement Disorders

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study

View Full Paper
Ask AI
Bookmark
Share

Authors

HTHuilin TangYLYing LüMOMichael S. Okun

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tang et al. (2024) studied this question.

synapsesocial.com/papers/68e5aa67b6db643587544c40https://doi.org/10.1002/mds.29992
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes2023 · 1,602 citations
  2. 2Metrics for covariate balance in cohort studies of causal effects2013 · 314 citations
  3. 3Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease2023 · 135 citations
  4. 4Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson’s disease in diabetic patients2023 · 22 citations
  5. 5Implications of the Propensity Score Matching Paradox in Pharmacoepidemiology2018 · 97 citations